News & Updates

A recent study has demonstrated the long-term safety of mirikizumab in patients with moderate to severe active ulcerative colitis (UC), with no new significant safety concerns.

A multi-species synbiotic preparation appears to improve outcomes in older patients with type 2 diabetes mellitus and high cardiovascular risk, according to a study.

Patient fatigue reported before the initiation of cancer treatment appears to be associated with an increased risk of subsequent treatment-related adverse events, according to new research.

Long-term use of aspirin tends to increase the risk of heart failure (HF) in individuals without cardiovascular disease (CVD), suggests a recent study.

Administering anifrolumab shots in addition to standard therapy is safe and yields clinically meaningful benefits in moderate to severe systemic lupus erythematosus, according to the phase III TULIP-SC trial.

In addition to improving glycaemic control, the use of SGLT2 inhibitors also appears to reduce mortality, hospitalization, cardiovascular events, and liver complications in patients with metabolic dysfunction-associated steatotic liver disease (MASLD), according to a study.

Combination treatment with trastuzumab deruxtecan (T-DXd) and radiation therapy (RT) may improve clinical outcomes, without compromising safety, in patients with HER2-positive and HER2-low metastatic breast cancer, reveals a study.

The results from the phase III ROP-ET trial demonstrate the potential of ropeginterferon alfa-2b (ropeg) for the treatment of essential thrombocythaemia (ET) across all risk levels in patients who are ineligible for standard cytoreduction.

In the treatment of acute ischaemic stroke in patients with recent direct oral anticoagulant (DOAC) use, intravenous thrombolysis appears to be safe and is associated with improvements in functional outcomes, according to a study.